ABSTRACT
CASE PRESENTATION: A 41-year-old man who currently smokes with previous sporadic use of cocaine and cannabinoids was admitted at the hospital suffering from hemoptysis which had developed 4 days before. The patient was on anticoagulant therapy with rivaroxaban due to paroxysmal atrial fibrillation diagnosed in 2018, for which he had undergone pulmonary vein electrical isolation by radiofrequency and ablation of cavotricuspid isthmus in January 2019. The procedure was completed in July 2019. Treatment with flecainide was introduced due to recurrences of atrial fibrillation. In February 2021, a new attempt at ablation was performed by electrical isolation of the left atrial posterior wall. The latest cardiologic checkup documented an echocardiographic framework of mild left atrial dilatation and normal-sized right ventricle with longitudinal shortening index at the lower limits, and a recurrence of asymptomatic atrial fibrillation at Holter ECG (March 2022).
Subject(s)
Atrial Fibrillation , Hemoptysis , Humans , Male , Adult , Hemoptysis/etiology , Hemoptysis/diagnosis , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Atrial Fibrillation/surgery , Catheter Ablation/methods , Echocardiography , Pulmonary Veins/surgery , Pulmonary Veins/diagnostic imagingABSTRACT
BACKGROUND: Direct oral anticoagulants (DOACs) have been the drug of choice for preventing ischemic stroke in patients with atrial fibrillation since 2014. In previous studies, the stroke risk while taking warfarin was 2 per 100 patient-years and 1.5% per year while taking DOACs. We hypothesized that even if ischemic stroke occurred during anticoagulation therapy with DOACs, the prognosis was likely to be better than that with warfarin. METHODS AND RESULTS: Data from 2002 to 2019, sourced from a nationwide claims database, were used to identify atrial fibrillation patients using International Classification of Diseases codes. Patients who experienced an ischemic stroke during anticoagulation were categorized by the drugs used (warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban). The primary outcome was mortality within 3 months and 1 year after the ischemic stroke. Among the 9578 patients with ischemic stroke during anticoagulation, 3343 received warfarin, and 6235 received DOACs (965 dabigatran, 2320 apixaban, 1702 rivaroxaban, 1248 edoxaban). The DOACs group demonstrated lower risks of 3-month (adjusted hazard ratio [HR], 0.550, [95% CI, 0.473-0.639]; P<0.0001) and 1-year mortality (adjusted HR, 0.596 [95% CI, 0.536-0.663]; P<0.0001) than the warfarin group. Apixaban and edoxaban within the DOAC group exhibited particularly reduced 1-year mortality risk compared with other DOACs (P<0.0001). CONCLUSIONS: Our study confirmed that DOACs have a better prognosis than warfarin after ischemic stroke. The apixaban and edoxaban groups had a lower risk of death after ischemic stroke than the other DOAC groups.
Subject(s)
Anticoagulants , Atrial Fibrillation , Factor Xa Inhibitors , Ischemic Stroke , Warfarin , Humans , Warfarin/therapeutic use , Warfarin/adverse effects , Ischemic Stroke/prevention & control , Ischemic Stroke/mortality , Ischemic Stroke/diagnosis , Male , Female , Aged , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Atrial Fibrillation/mortality , Prognosis , Administration, Oral , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/adverse effects , Factor Xa Inhibitors/administration & dosage , Middle Aged , Aged, 80 and over , Pyridones/adverse effects , Pyridones/therapeutic use , Pyridones/administration & dosage , Retrospective Studies , Pyrazoles/therapeutic use , Pyrazoles/adverse effects , Dabigatran/therapeutic use , Dabigatran/adverse effects , Dabigatran/administration & dosage , Rivaroxaban/therapeutic use , Rivaroxaban/adverse effects , Rivaroxaban/administration & dosage , Risk Factors , Risk Assessment , Taiwan/epidemiology , Pyridines , ThiazolesABSTRACT
Female sex has been suggested as a risk modifier for stroke in patients with atrial fibrillation (AF) with comorbid prevalent stroke risk factors. Management has evolved over time towards a holistic approach that may have diminished any sex difference in AF-related stroke. In a nationwide cohort of AF patients free from oral anticoagulant treatment, we examine the time trends in stroke risk overall and in relation to risk differences between male and female patients. Here we show that among 158,982 patients with AF (median age 78 years (IQR: 71 to 85); 52% female) the 1-year thromboembolic risk was highest between 1997-2000 with a risk of 5.6% and lowest between 2013-2016 with a risk of 3.8%, declining over the last two decades. The excess stroke risk for female vs male patients has also been declining, with risk-score adjusted relative risk estimates suggesting limited sex-difference in recent years.
Subject(s)
Atrial Fibrillation , Stroke , Humans , Atrial Fibrillation/epidemiology , Atrial Fibrillation/complications , Female , Male , Aged , Stroke/epidemiology , Aged, 80 and over , Risk Factors , Cohort Studies , Sex Factors , Anticoagulants/therapeutic use , Middle Aged , Thromboembolism/epidemiology , Thromboembolism/etiologyABSTRACT
AIM: To evaluate the prognostic value of GDF-15 in relation the development of bleeding and events in stable CAD patients, receiving combined antithrombotic therapy. MATERIALS AND METHODS: The data was obtained from the prospective registry REGATA, 343 CAD patients (249 males), median age 68 [IQR 62; 75] years) were enrolled. Patients with sinus rhythm and concomitant PAD received acetylsalicylic acid in combination with rivaroxaban 2.5 mg bid (31.8%) or clopidogrel (24.8%). Other 43.4% with concomitant atrial fibrillation (AF) received direct oral anticoagulants in combination with antiplatelet therapy after elective percutaneous coronary interventions. Median follow-up was 12 months [IQR 9.0; 18.0]. The safety end point was major and clinically relevant bleedings (type 2-5) according to the BARC classification. Plasma samples for GDF-15 identification were taken at the inclusion and analyzed using ELISA assay. RESULTS: Frequency of BARC 2-5 bleedings was 16% (BARC 2 - 46; BARC 3 - 9; BARC 4-5 - 0), median GDF-15 level was 1185.0 pg/ml [850.0; 1680.0]. In patients with AF and concomitant MFA, the level of GDF-15 was significantly higher than in the subgroups of patients with only AF or MFA (p=0.0022). According to the quintile analysis, GDF-15 values in the top three quintiles of distribution (cut-off value >943 pg/ml) were associated with higher frequency of bleeding events: 23.2% versus 5.1%; p=0.0001. The multivariable logistic regression model demonstrated that bleeding events were independently associated with GDF-15 level>943 pg/ml (OR 2.65, 95% CI 1.11-6.30; p=0.0275), AF (OR 2.61, 95% CI 1.41-4.83; p=0.0023) and chronic kidney disease (OR 1.92, 95% CI 1.03-3.60; p=0.0401). Clinical factors determining the risk of bleeding events also determined a GDF-15 elevation. CONCLUSION: Assessment of GDF-15 level may improve bleeding risk stratification in CAD patients with concomitant AF and/or PAD receiving combined antithrombotic therapy.
Subject(s)
Growth Differentiation Factor 15 , Hemorrhage , Registries , Humans , Male , Female , Aged , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Hemorrhage/etiology , Middle Aged , Growth Differentiation Factor 15/blood , Prospective Studies , Coronary Artery Disease/complications , Coronary Artery Disease/blood , Drug Therapy, Combination , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Aspirin/administration & dosage , Aspirin/adverse effects , Clopidogrel/administration & dosage , Clopidogrel/adverse effects , Prognosis , Russia/epidemiology , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Rivaroxaban/administration & dosage , Rivaroxaban/adverse effects , Percutaneous Coronary Intervention/methods , Percutaneous Coronary Intervention/adverse effectsABSTRACT
Aim: The index study aimed to investigate the clinical impact of initial high-sensitivity C-reactive protein (hs-CRP) on outcomes in nonvalvular atrial fibrillation (AF). Methods: Single-center, prospective, observational study recruiting all recently diagnosed treatment-naive AF patients. Hs-CRP was measured at baseline and patients were followed for 24 months. Results: A total of 126 patients with a mean age of 66.2 (±12.0) years were enrolled. The composite outcome of major adverse cardiac or cerebrovascular events (MACCE) occurred in 19 (17.7%) at 24 months. Raised initial hs-CRP emerged as an independent predictor of MACCE on regression analysis (OR: 1.569, 95% CI: 1.289-1.912; p < 0.001). Conclusion: Raised hs-CRP was an independent predictor of MACCE at 24 months. It allows for early identification of high-risk patients.
Atrial fibrillation (AF) is the most common cause of irregular heartbeat in adults. It has a significant association with clot formation in the heart and acute vessel closure throughout the vascular system particularly of the brain causing stroke. Stroke has a significant impact on quality of life and also is associated with an increased likelihood of death. Inflammation has been linked to the development and progression of AF. In this study, we evaluated the role of a simple inflammatory blood parameter high sensitivity C-reactive protein (hs-CRP) with adverse outcomes in 126 AF patients at our center over a period of 2 years. We concluded that hs-CRP was an independent predictor of worse cardiovascular outcomes in AF patients and can help in the earlier identification of high-risk patients, for whom appropriate measures can be taken to prevent adverse events.
Subject(s)
Atrial Fibrillation , Biomarkers , C-Reactive Protein , Humans , Atrial Fibrillation/complications , Atrial Fibrillation/blood , C-Reactive Protein/metabolism , C-Reactive Protein/analysis , Female , Male , Aged , Prospective Studies , Biomarkers/blood , Prognosis , Risk Factors , Middle Aged , Follow-Up Studies , Risk Assessment/methodsSubject(s)
Atrial Fibrillation , Cardiomyopathies , Heart Failure , Humans , Atrial Fibrillation/complications , Atrial Fibrillation/physiopathology , Cardiomyopathies/physiopathology , Cardiomyopathies/etiology , Cardiomyopathies/complications , Heart Failure/etiology , Heart Failure/physiopathology , Male , Female , Aged , Middle Aged , Risk FactorsABSTRACT
INTRODUCTION: With the increasing prevalence of atrial fibrillation (AF), it entails expanding oral anticoagulants (OACs) use, carrying a higher risk of associated hemorrhagic events, including intracranial hemorrhage (ICH). Despite advances in OACs development with a better safety profile and reversal agent for these anticoagulants, there is still no consensus on the optimal management of patients with OACs-associated ICH. AREAS COVERED: In this review, the authors have carried out an exhaustive search on the advances in recent years. The authors provide an update on the management of ICH in anticoagulated patients, as well as an update on the latest evidence on anticoagulation resumption, recent therapeutic strategies, and investigational drugs that could play a role in the future. EXPERT OPINION: Following an ICH event in an anticoagulated patient, a comprehensive clinical evaluation is imperative. Anticoagulation should be promptly withdrawn and reversed. Once the patient is stabilized, a reintroduction of anticoagulation should be considered, typically within a timeframe of 4-8 weeks, if feasible. If re-anticoagulation is not possible, alternative options such as Left Atrial Appendage Occlusion are available.
Subject(s)
Anticoagulants , Atrial Fibrillation , Intracranial Hemorrhages , Humans , Anticoagulants/therapeutic use , Anticoagulants/adverse effects , Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Intracranial Hemorrhages/chemically induced , Administration, OralSubject(s)
Anticoagulants , Atrial Fibrillation , Frail Elderly , Vitamin K , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Vitamin K/antagonists & inhibitors , Aged , Administration, Oral , Randomized Controlled Trials as Topic , Drug Substitution , Aged, 80 and overSubject(s)
Anticoagulants , Atrial Fibrillation , Frail Elderly , Vitamin K , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Vitamin K/antagonists & inhibitors , Aged , Administration, Oral , Randomized Controlled Trials as Topic , Drug Substitution , Aged, 80 and overSubject(s)
Anticoagulants , Atrial Fibrillation , Frail Elderly , Vitamin K , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Vitamin K/antagonists & inhibitors , Administration, Oral , Aged , Randomized Controlled Trials as Topic , Drug Substitution , Aged, 80 and overSubject(s)
Anticoagulants , Atrial Fibrillation , Frail Elderly , Vitamin K , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Vitamin K/antagonists & inhibitors , Aged , Administration, Oral , Randomized Controlled Trials as Topic , Drug Substitution , Aged, 80 and overSubject(s)
Anticoagulants , Atrial Fibrillation , Frail Elderly , Vitamin K , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Vitamin K/antagonists & inhibitors , Administration, Oral , Aged , Randomized Controlled Trials as Topic , Drug SubstitutionABSTRACT
BACKGROUND: The differences in the characteristics of ischemic stroke associated with a mobile versus nonmobile residual left atrial thrombus (LAT) are unclear. We investigated whether the mobility of an LAT detected by transthoracic echocardiography is associated with the clinical features of stroke. METHODS: This study included 20 consecutive patients with nonvalvular atrial fibrillation who were admitted to our hospital for treatment of acute ischemic stroke and then found to have an LAT on transthoracic echocardiography. The patients were divided into two groups: those with a mobile LAT (Group M) and those with a nonmobile LAT (Group N). The clinical, neuroradiological, and echocardiographic variables were assessed. RESULTS: The LAT was mobile in 11 patients (Group M) and nonmobile in nine patients (Group N). The median National Institutes of Health Stroke Scale score on admission was higher in Group M than N (17 vs. 7, respectively; p=0.196). Four patients in Group M and one in Group N developed in-hospital stroke recurrence (36% vs. 11%, respectively; p=0.319). The prevalence of large vessel occlusion (15 events in Group M and 10 events in Group N, including in-hospital recurrent events) was significantly higher in Group M than N (73% vs. 30%, respectively; p=0.049), which seemed to lead to poorer functional outcomes in Group M than N (ratio of modified Rankin scale score of 0-2 at discharge: 18% vs. 44%, respectively; p=0.336). CONCLUSIONS: The mobility of LAT may affect stroke severity in patients with nonvalvular atrial fibrillation.
Subject(s)
Atrial Fibrillation , Echocardiography , Heart Atria , Severity of Illness Index , Thrombosis , Humans , Atrial Fibrillation/complications , Male , Female , Aged , Thrombosis/etiology , Thrombosis/diagnostic imaging , Heart Atria/diagnostic imaging , Heart Atria/physiopathology , Aged, 80 and over , Middle Aged , Ischemic Stroke/complications , Ischemic Stroke/etiology , Recurrence , Stroke/complications , Stroke/etiology , Heart Diseases/complications , Heart Diseases/etiologyABSTRACT
Supraventricular tachycardia (SVT) is a frequent complication of pulmonary hypertension (PH). The most prevalent SVTs are atrial fibrillation (AF) and typical atrial flutter (AFL), followed by focal and macroreentrant atrial tachycardia (AT) and nodal arrhythmia (AV nodal reentry tachycardia or AV reentry tachycardia). SVT is frequently associated with functional deterioration and right ventricular failure in PH patients. According to some data, reestablishing sinus rhythm is associated with clinical improvement. Catheter ablation of typical AFL, nodal tachyarrhythmias, or other less complex focal ATs have been shown to be feasible, acutely effective, and safe in patients with PH. However, the long-term clinical outcome is modified by the recurrence of index arrhythmia and the onset of a new SVT. Due to right atrial dilatation, technical issues can arise when ablation is carried out. The role of catheter ablation in patients with AF or more complex AT is even less effective. The results mirror the success rate in the general AF population with non-paroxysmal AF. However, the data is limited, and electrophysiological procedures are also more often complicated by specific adverse events in a severely frail population. Despite these limitations, catheter ablation is the treatment of choice in less complex SVT, but the indications for AF ablation must be more individualized.
Subject(s)
Catheter Ablation , Hypertension, Pulmonary , Humans , Hypertension, Pulmonary/surgery , Treatment Outcome , Tachycardia, Supraventricular/surgery , Atrial Fibrillation/surgery , Atrial Fibrillation/complications , Male , FemaleSubject(s)
Atrial Fibrillation , Echocardiography , Heart Atria , Shock, Septic , Humans , Atrial Fibrillation/physiopathology , Atrial Fibrillation/complications , Shock, Septic/physiopathology , Shock, Septic/complications , Retrospective Studies , Male , Female , Echocardiography/methods , Middle Aged , Aged , Heart Atria/physiopathology , Heart Atria/diagnostic imaging , Predictive Value of TestsABSTRACT
BACKGROUND: The extent to which differences in results from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET) atrial fibrillation (AF)-the landmark trials for the approval of apixaban and rivaroxaban, respectively, for non-valvular AF-were influenced by differences in their protocols is debated. The potential influence of selection criteria on trial results was assessed by emulating these trials in data from the Global Anticoagulant Registry in the Field (GARFIELD)-AF registry. METHODS: Vitamin K antagonist (VKA) and non-vitamin K oral antagonist (NOAC) users from GARFIELD-AF were selected according to eligibility for the original ARISTOTLE or ROCKET AF trials. A propensity score overlap weighted Cox model was used to emulate trial randomisation between treatment groups. Adjusted HRs for stroke or systemic embolism (SE) within 2 years of enrolment were calculated for each NOAC versus VKA. RESULTS: Among patients on apixaban, rivaroxaban and VKA, 2570, 3560 and 8005 were eligible for ARISTOTLE, respectively, and 1612, 2005 and 4368, respectively, for ROCKET AF. When selecting for ARISTOTLE criteria, apixaban users had significantly lower stroke/SE risk versus VKA (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68 to 1.40). When selecting for ROCKET AF criteria, safety and efficacy versus VKA were similar across the NOACs. CONCLUSION: Apixaban and rivaroxaban showed similar results versus VKA in high-risk patients selected according to ROCKET AF criteria, whereas differences emerged when selecting for the more inclusive ARISTOTLE criteria. Our results highlight the importance of trial selection criteria in interpreting trial results and underline the problems faced in comparing treatments across rather than within clinical trials.
Subject(s)
Atrial Fibrillation , Factor Xa Inhibitors , Patient Selection , Pyrazoles , Pyridones , Rivaroxaban , Stroke , Humans , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/administration & dosage , Stroke/prevention & control , Stroke/etiology , Pyrazoles/therapeutic use , Pyridones/therapeutic use , Pyridones/adverse effects , Pyridones/administration & dosage , Rivaroxaban/administration & dosage , Rivaroxaban/therapeutic use , Male , Female , Aged , Treatment Outcome , Registries , Administration, Oral , Risk Factors , Randomized Controlled Trials as Topic/methods , Risk Assessment/methods , Anticoagulants/therapeutic use , Vitamin K/antagonists & inhibitorsSubject(s)
Heart Defects, Congenital , Adult , Humans , Arrhythmias, Cardiac/therapy , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/etiology , Atrial Fibrillation/therapy , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Catheter Ablation/methods , Electrocardiography , Heart Defects, Congenital/complications , Heart Defects, Congenital/diagnosisABSTRACT
AIMS: In patients with atrial fibrillation (AF) and stroke risk factors, randomized trials have demonstrated that anticoagulation decreases the risk of ischemic stroke. However, all trials to date have excluded patients with significant liver disease, leaving guidelines to extrapolate recommendations. We aim to evaluate the impact of anticoagulation on safety events in patients with AF and cirrhosis. METHODS AND RESULTS: In this retrospective cohort study, we obtained de-identified health record data to extract anticoagulation strategy, comorbidities, prescriptions, lab values, and procedures for a cohort of patients with cirrhosis who develop AF. After selecting a propensity matched population to match patients with various anticoagulation strategies, we tracked data on outcomes for death, transfusion requirements, hospital and ICU admissions. After propensity score weighting and multivariable adjustment, anticoagulation strategy was associated with increased hospital admission count (OR = 1.74 per admission, P < .001), binary risk of hospital admission (OR = 1.54, P = .010) and risk of ICU admission (OR = 1.41, P = .047). We detected no significant differences in mortality, transfusion of blood products, or average length of stay. Direct oral anticoagulant (DOAC) prescriptions were associated with increased binary risk of hospital admission compared to warfarin prescriptions. In a third comparison, DOAC strategy alone was associated with increased hospital admission count (OR = 1.41 per admission, P < .001) and binary risk of hospital admission (OR = 1.52, P = .038) compared to no anticoagulation strategy. CONCLUSION: Anticoagulation strategy in patients with cirrhosis and AF was associated with increased rate of hospital admission and ICU admission but not associated with increased risk of mortality or transfusion requirement.